The acquisition will strengthen Lupin’s India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products
Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.
Lupin has reported consolidated financial results for the period ended December 31, 2021
FDA changes inspection classification of the facility to Voluntary Action Indicated
Lupin Diagnostics will provide a comprehensive range of diagnostic tests. These include molecular diagnostics, cytogenetics, flow cytometry, microbiology, serology, histopathology and cytology, haematology, immunology, amongst others.
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
According to WHO, over 1.5 million people died of TB in 2020
The profits were bolstered by the Boehringer Ingelheim MEK program income
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
